Upcoming FDA decision · March 1, 2027
Feladilimab PDUFA date: FDA decision expected March 1, 2027
159 days to goGSK plc (GSK) →
The FDA is expected to decide on Feladilimab from GSK plc in Multiple Myeloma by the PDUFA target action date of March 1, 2027. For multiple myeloma. BLA filing. Extracted from SEC filing: 6-K
A PDUFA date is the FDA's target deadline to complete its review of a drug application — approval, a complete response letter (CRL), or an extension are all possible. What is a PDUFA date? This page is research information, not financial advice.
March 1
Target action date
Phase 2
Stage
Detected
Date confidence
—
FDA designations